Malignant response to ajmaline challenge in SCN5A mutation carriers: Experience from a large familial study  by Gandjbakhch, E. et al.
Malignant response to ajmaline challenge in SCN5A mutation carriers:
Experience from a large familial study
E. Gandjbakhch a,f,⁎, V. Fressart b, G. Duthoit a,f, C. Marquié c, J.C. Deharo d, F. Pousset a,f, J.L. Hebert a, F. Simon b,
C. Himbert a, D. Klug c, P. Charron a,e,f, F. Hidden-Lucet a,f
a APHP, Hôpital Pitié-Salpêtrière, Institut de Cardiologie, 75013 Paris, France
b APHP, Hôpital Pitié-Salpêtrière, Département de Biochimie Métabolique, 75013 Paris, France
c CHRU, Département de Cardiologie, 59037 Lille, France
d Hôpital de la Timone, Département de Rythmologie, 13385 Marseille, France
e UPMC Univ Paris 6, APHP, Hôpital Pitié-Salpêtrière, Département de Génétique, 75013 Paris, France
f ICAN, Hôpital Pitié-Salpêtrière, 75013 Paris, France
a r t i c l e i n f o
Article history:
Received 25 November 2013
Accepted 30 December 2013








This observation reports a large family with unusual presentation
of a SCN5A mutation characterized by a large phenotypic hetero-
geneity and a malignant response to ajmaline infusion. The proband
(III:1), a 34 year old Caucasian male, was referred for recurrent
syncope. His ECG displayed a 1st degree atrio-ventricular (AV) block,
an atypical right-bundle-branch block (RBBB) with left axis deviation
and a non-diagnostic Brugada (Br)-like pattern in high V2. Intrave-
nous ajmaline infusion (1 mg/kg at 1 mg/s) led to a very large
widening of QRS complexes without Br-type1 pattern and triggered a
syncopal polymorphic ventricular tachycardia (VT) (Fig. 1) that was
reversed with rapid sodium-bicarbonate infusion. Echocardiography
and biventricular angiography showed a limited right ventricular
outﬂow tract (RVOT) akinesia without any other abnormality. A
ventricular ﬁbrillation (VF) needing external cardioversion was
induced twice at electrophysiological study (ﬁrst with only 600 ms
burst stimulation then with S3 extra-stimuli 400/240/190 ms) and a
double-chamber implantable cardiac deﬁbrillator was therefore
implanted. HV interval was normal (48 ms). He further experienced
several appropriate shocks for nocturnal polymorphic VTs that were
successfully treated with quinidine. The molecular study performed
after informed consent identiﬁed a novel heterozygous nonsense
SCN5A mutation (p.W781X). For diagnostic purposes, intravenous
ajmaline challenge was performed in two additional relatives (1 mg/
kg at 1 mg/s) with a suspect ECG. Individual II:1 displayed
intermittent Br-type1 pattern associated with 1st degree AV block
whereas individual II:4 only displayed a Br-type3 pattern associated
with left-anterior fascicular block. Both experienced a similar pro-
arrhythmic effect during ajmaline infusionwith triggering of syncopal
polymorphic VT. Ventricular arrhythmias (VAs) were rapidly reversed
with rapid sodium-bicarbonate infusion in relative II:1 but needed
several external shocks to restore sinus rhythm in case of individual
II:4 (Fig. 1). None of them developed high-degree AV-block upon
ajmaline infusion, despite the presence of conduction abnormalities at
baseline. They were both subsequently found to carry the familial
SCN5A mutation. After this observation and the identiﬁcation of the
disease-causing mutation, intravenous ajmaline challenge was aban-
doned and familial screening was based on ECG and molecular study
that allowed the identiﬁcation of eight additional SCN5A mutation-
carriers and two relatives with a Br-type1 ECG (Fig. 2) with no DNA
available. This SCN5A mutation was associated with a broad
phenotypic spectrum within the family, associating Br-pattern ECG,
intra-ventricular or AV conduction defects, sinus-node dysfunction
(SND) or mixed phenotype (Fig. 2). Four mutation-carriers experi-
enced syncope or vaso-vagal symptoms. Five relatives, all men,
displayed a typical Br-type1 pattern, associated in two cases with
conduction defects while other mutation-carriers, mostly females,
only displayed Br-type2/3 patterns, AV-conduction defects and/or
SND (Fig. 2). One cousin developed high-degree conduction disease
needing implantation of a pace-maker at 48 years-old. Three muta-
tion-carriers (aged 10 to 30) appeared clinically unaffected. Three
individuals from the older generation (no DNA available) developed
high-degree conduction disease necessitating implantation of a pace-
maker in later life (individuals I:2, I:3, I:4). Late potentials were
present in four mutation-carriers and six displayed minor right
ventricular (RV) abnormalities as mild RV enlargement, excessive
trabeculations or wall motion abnormalities (Fig. 2). No additional
mutation was identiﬁed in the desmosomal genes PKP2, DSG2, DSP or
DSC2.
Intravenous sodium-channel blocker infusion is an effective
routine diagnostic test recommended to unmask Br-type1 pattern in
symptomatic patients or relatives with a suspect ECG [1]. It was also
described as accurate to diagnose asymptomatic SCN5A mutation-
carriers [2]. Ventricular pro-arrhythmic effects of sodium-channel
blockers have been occasionally reported, however VT/VF occurrence
under ajmaline infusion is rare in large series, ranging from 0.15 to
0.25% in populations with suspected BrS [3,4] to 1.8% in BrS cohorts
[5]. Conversely, SCN5A mutation was associated in the present family
with a high and reproducible pro-arrhythmic effect of ajmaline,
independent of the presence of a baseline or induced Br-ECG pattern,
sex or underlying symptoms. It is very unlikely that this atypical
response would only be caused by the rapid infusion protocol used. In
our experience based on more than 300 patients, this was the ﬁrst
time that such a pro-arrhythmic response was observed with this
protocol and data from a randomized study and a large series of 386
tests found that a rapid infusion protocol was not associated with a
higher risk of VAs [3]. However, the predictive value of such pro-
arrhythmic response in BrS and SCN5A mutation-carriers remains
unknown. A recent study reported no additional risk of VAs in 9
patients that displayed such response after a 29 month follow-up [5].
In the present family, only one symptomatic SCN5A mutation-carrier
developed spontaneous VAs. No sudden death occurred in the family
and no other family members experienced VAs after 5 years of follow-
up, including individuals II:1 and II:4, suggesting low predictive value
of ajmaline-induced VT/VF.
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SCN5A mutation was associated in the present family with a large
phenotypic heterogeneity associating Br-pattern and/or conduction
disturbances. SCN5A mutations are known to be associated with a
large panel of phenotypes including long-QT syndrome, BrS, atrial
ﬁbrillation, dilated cardiomyopathy and conduction disease [6].
Recent retrospective analysis showed that conduction disturbances
were frequent in patients with BrS as observed in this family [7].
However, the pathophysiological mechanisms underlying the repro-
ducible pro-arrhythmic effect of ajmaline and the variable expression
observed in this family are poorly understood. Although this
malignant response was independent of the baseline ECG, it could
be linked to the frequent conduction disturbances associated with this
SCN5A mutation [8]. This is suggested by a recent study where a pro-
arrhythmic effect of ajmaline was more frequently observed in
patients with BrS when associated with concomitant SND [5]. This
study also found a higher frequency of SCN5A mutations in patients
experiencing ajmaline-induced VAs, suggesting that some SCN5A
mutations are associated with an increased sensitivity to sodium-
channel blockers [5]. One of them, the SCN5A p.R878C missense
mutation, was associated with familial ajmaline-induced VT as
observed in the present study. However, the present truncating
p.W781X mutation is predicted to be associated with haplo-
insufﬁciency and loss of function mechanism, similar to other SCN5A
mutations not associated with such phenotype. This suggests the
presence of additional unrecognized modiﬁer gene/SNPs leading to
this unusual presentation. Genetic factors as well as gender difference
could also play a role in the variable phenotypic expression observed
in this family [9]. Thus, in the present study, only males displayed a Br-
type1 patternwhen females displayed type2/3 ECG and/or conduction
abnormalities, which is concordant with the male predominance
reported in type1-BrS cohorts [10]. Although BrS is usually considered
as a pure electrical disorder without structural heart disease, the
presence of frequent RV abnormalities in this family is consistent with
several studies reporting mild RV abnormalities in BrS patients [11].
In conclusion, we provide the ﬁrst detailed description of a familial
malignant pro-arrhythmic response to ajmaline associated with a
novel SCN5Amutation. We conclude that one should be cautious with
sodium-channel blocker challenge in suspected SCN5A mutation-
carriers, especially in the presence of conduction abnormalities on
baseline ECG and emphasize the usefulness of genetic screening in
these families. Larger and longer studies are needed to explore the
underlying mechanism and understand the predictive value of
ajmaline-induced VAs.
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Fig. 2. Family tree and clinical characteristics of SCN5Amutation-carriers. Top: family tree. Circle: female; square: male; +: presence of the p.W781X SCN5Amutation.−: absence of
the mutation. Bottom: clinical characteristics of SCN5A mutation-carriers. AVB: atrio-ventricular block, RBBB: right-bundle-branch block; iRBBB: incomplete RBBB; VT: ventricular
tachycardia; VF: ventricular ﬁbrillation; SND: sinus-node-dysfunction; SA-ECG: signal-averaged ECG; ICD: implantable cardiac deﬁbrillator; PM: pace-maker; NA: non-available data.
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